SG11201600310QA - Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors - Google Patents
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitorsInfo
- Publication number
- SG11201600310QA SG11201600310QA SG11201600310QA SG11201600310QA SG11201600310QA SG 11201600310Q A SG11201600310Q A SG 11201600310QA SG 11201600310Q A SG11201600310Q A SG 11201600310QA SG 11201600310Q A SG11201600310Q A SG 11201600310QA SG 11201600310Q A SG11201600310Q A SG 11201600310QA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- treating cancer
- axis binding
- binding antagonists
- tigit inhibitors
- Prior art date
Links
- 101100369641 Mus musculus Tigit gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0387—Animal model for diseases of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361846941P | 2013-07-16 | 2013-07-16 | |
US201361865582P | 2013-08-13 | 2013-08-13 | |
US201461950754P | 2014-03-10 | 2014-03-10 | |
US201461985884P | 2014-04-29 | 2014-04-29 | |
US201461992109P | 2014-05-12 | 2014-05-12 | |
PCT/US2014/046896 WO2015009856A2 (en) | 2013-07-16 | 2014-07-16 | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201600310QA true SG11201600310QA (en) | 2016-02-26 |
Family
ID=51300845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201600310QA SG11201600310QA (en) | 2013-07-16 | 2014-07-16 | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
Country Status (26)
Country | Link |
---|---|
US (7) | US9873740B2 (de) |
EP (2) | EP3789036A1 (de) |
JP (4) | JP6636920B2 (de) |
KR (3) | KR20230118704A (de) |
CN (1) | CN105492025A (de) |
AU (3) | AU2014290069B2 (de) |
BR (1) | BR112016000853A2 (de) |
CA (1) | CA2916681A1 (de) |
DK (1) | DK3021869T3 (de) |
ES (1) | ES2819209T3 (de) |
HK (1) | HK1217283A1 (de) |
HR (1) | HRP20201404T1 (de) |
HU (1) | HUE050496T2 (de) |
IL (2) | IL243324B (de) |
LT (1) | LT3021869T (de) |
MX (2) | MX2016000510A (de) |
MY (1) | MY183503A (de) |
PL (1) | PL3021869T3 (de) |
PT (1) | PT3021869T (de) |
RS (1) | RS60826B1 (de) |
RU (2) | RU2019129525A (de) |
SG (1) | SG11201600310QA (de) |
SI (1) | SI3021869T1 (de) |
TW (2) | TWI685349B (de) |
WO (1) | WO2015009856A2 (de) |
ZA (2) | ZA201800079B (de) |
Families Citing this family (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE493433T1 (de) | 2002-09-11 | 2011-01-15 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
EP1891107B1 (de) | 2005-05-12 | 2011-07-06 | ZymoGenetics, Inc. | Zusammensetzungen und verfahren zur modulierung von immunreaktionen |
EP2279412B1 (de) | 2008-04-09 | 2017-07-26 | Genentech, Inc. | Neue zusammensetzungen und verfahren zur behandlung von immunkrankheiten |
HUE061117T2 (hu) | 2009-03-25 | 2023-05-28 | Genentech Inc | Anti-FGFR3 antitestek és eljárások alkalmazásukra |
EP2655409A4 (de) | 2010-12-22 | 2015-07-01 | Univ Leland Stanford Junior | Superagonisten und antagonisten von interleukin-2 |
ES2707580T3 (es) | 2011-09-23 | 2019-04-04 | Oncomed Pharm Inc | Agentes de unión a VEGF/DLL4 y usos de los mismos |
CA2893597C (en) | 2012-12-07 | 2021-06-29 | Chemocentryx, Inc. | Diazole lactams |
MY183503A (en) | 2013-07-16 | 2021-02-23 | Genentech Inc | Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
WO2015042707A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics Pte Ltd | Interleukin-2 fusion proteins and uses thereof |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
NZ747418A (en) | 2014-03-12 | 2023-05-26 | Yeda Res & Dev | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
EP3119913B1 (de) * | 2014-03-21 | 2021-01-06 | The Brigham and Women's Hospital, Inc. | Verfahren und zusammensetzungen zur behandlung von immunbedingten erkrankungen oder störungen und/oder therapieüberwachung |
WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
KR102433464B1 (ko) | 2014-05-28 | 2022-08-17 | 아게누스 인코포레이티드 | 항-gitr 항체 및 이의 사용 방법 |
UA122395C2 (uk) * | 2014-08-19 | 2020-11-10 | Мерк Шарп Енд Доум Корп. | Антитіло проти tigit |
EP3925622A1 (de) | 2014-09-13 | 2021-12-22 | Novartis AG | Kombinationstherapien |
WO2016073282A1 (en) * | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
WO2016134234A1 (en) * | 2015-02-19 | 2016-08-25 | Bioclin Therapeutics, Inc. | Methods, compositions, and kits for treatment of cancer |
PT3653221T (pt) | 2015-02-19 | 2022-11-08 | Compugen Ltd | Anticorpos anti-pvrig e métodos de utilização |
EP3978929A1 (de) | 2015-02-19 | 2022-04-06 | Compugen Ltd. | Pvrig-polypeptide und verfahren zur behandlung |
DK3283508T3 (en) | 2015-04-17 | 2021-05-31 | Alpine Immune Sciences Inc | Immunomodulatory Proteins with Tunable Affinities |
TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Tigit結合劑和彼之用途 |
PE20180926A1 (es) | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos |
US10144779B2 (en) | 2015-05-29 | 2018-12-04 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
JO3620B1 (ar) * | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
JP6976241B2 (ja) * | 2015-08-14 | 2021-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗tigit抗体 |
EP3344772B1 (de) * | 2015-09-01 | 2020-08-26 | Academia Sinica | Antagonistische pdl1-aptamere und deren anwendungen in der krebstherapie |
US10323091B2 (en) | 2015-09-01 | 2019-06-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
EP3344658B1 (de) | 2015-09-02 | 2022-05-11 | Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. | Anti tigit (human t-cell immunoglobulin and itim domain) antikörper |
EP3353204B1 (de) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-spezifischer anti-vegf/dll4-antikörper zur verwendung bei der behandlung von platin-resistentem eierstockkrebs |
JP6764474B2 (ja) * | 2015-09-25 | 2020-09-30 | ジェネンテック, インコーポレイテッド | 抗tigit抗体及び使用方法 |
RU2729379C1 (ru) * | 2015-10-01 | 2020-08-06 | Потенза Терапевтикс, Инк. | Анти-tigit антигенсвязывающие белки и способы их применения |
MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
CN116063542A (zh) | 2015-12-02 | 2023-05-05 | 阿吉纳斯公司 | 抗体和其使用方法 |
KR102281961B1 (ko) * | 2016-01-08 | 2021-07-26 | 다이호야쿠힌고교 가부시키가이샤 | 면역 조절제를 함유하는 항종양제 및 항종양 효과 증강제 |
CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
CN109069211B (zh) | 2016-01-26 | 2022-04-29 | 网络牙科(美国)公司 | 自动牙科治疗系统 |
CA3015619A1 (en) * | 2016-03-01 | 2017-09-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (pvr) |
UA125898C2 (uk) | 2016-03-04 | 2022-07-06 | Джн Байосайєнсіз, Ллк | Антитіла до tigit |
WO2017160599A1 (en) | 2016-03-14 | 2017-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of cd300b antagonists to treat sepsis and septic shock |
EP4112641A1 (de) | 2016-03-15 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | Verfahren zur krebsbehandlung mit pd-1-achsenbindenden antagonisten und anti-gpc3-antikörpern |
US10894823B2 (en) | 2016-03-24 | 2021-01-19 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
PT3439653T (pt) * | 2016-04-07 | 2021-03-25 | Chemocentryx Inc | Redução da carga tumoral por administração de antagonistas de ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1 |
AU2017250296A1 (en) * | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
CA3021631C (en) * | 2016-04-20 | 2023-01-17 | University Of Tsukuba | Regulatory t cell activator and use thereof |
TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
US20220354888A1 (en) * | 2016-08-03 | 2022-11-10 | Aalborg Universitet | ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS |
PT3347379T (pt) * | 2016-08-17 | 2020-02-18 | Compugen Ltd | Anticorpos anti-tígitos, anticorpos anti-pvrig e as suas combinações |
CN107815467B (zh) | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
WO2018041120A1 (en) * | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric tigit |
CA3041340A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
CN110662552A (zh) * | 2016-11-30 | 2020-01-07 | 昂科梅德制药有限公司 | 包含tigit结合剂的癌症治疗方法 |
WO2018102746A1 (en) * | 2016-12-02 | 2018-06-07 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to tigit |
AU2017373945A1 (en) | 2016-12-07 | 2019-06-20 | Agenus Inc. | Antibodies and methods of use thereof |
MX2019006340A (es) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos. |
AU2017375946A1 (en) * | 2016-12-12 | 2019-06-20 | Genentech, Inc. | Methods of treating cancer using anti-PD-l1 antibodies and antiandrogens |
US10232053B2 (en) | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
US10537637B2 (en) | 2017-01-05 | 2020-01-21 | Gensun Biopharma Inc. | Checkpoint regulator antagonists |
CA3050009A1 (en) * | 2017-01-18 | 2018-07-26 | Genentech, Inc. | Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
BR112019017550A2 (pt) * | 2017-02-28 | 2020-04-14 | Seattle Genetics Inc | anticorpo isolado, composição farmacêutica, anticorpo biespecífico, conjugado de anticorpo-droga, polinucleotídeo isolado, vetor, célula hospedeira, métodos de produção de um anticorpo e de tratamento de um câncer em um sujeito, e, kit |
ES2953595T3 (es) | 2017-03-01 | 2023-11-14 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
JOP20190203A1 (ar) * | 2017-03-30 | 2019-09-03 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها |
SG11201909154SA (en) | 2017-04-05 | 2019-10-30 | Hoffmann La Roche | Bispecific antibodies specifically binding to pd1 and lag3 |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
MA50957A (fr) | 2017-05-01 | 2020-10-14 | Agenus Inc | Anticorps anti-tigit et leurs méthodes d'utilisation |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3618855A4 (de) * | 2017-05-02 | 2021-02-17 | Merck Sharp & Dohme Corp. | Stabile formulierungen von anti-tigit-antikörpern allein und in kombination mit programmierten antikörpern des todesrezeptors 1 (pd-1) und verfahren zur verwendung davon |
JP7348072B2 (ja) | 2017-06-01 | 2023-09-20 | コンピュジェン リミテッド | 三重併用抗体療法 |
JP2020523018A (ja) | 2017-06-09 | 2020-08-06 | プロビデンス ヘルス アンド サービシーズ−オレゴン | がんの処置のための腫瘍反応性ヒトt細胞の同定のためのcd39およびcd103の使用 |
WO2018229163A1 (en) | 2017-06-14 | 2018-12-20 | King's College London | Methods of activating v delta 2 negative gamma delta t cells |
JP7433051B2 (ja) | 2017-06-19 | 2024-02-19 | メディシナ セラピューティクス インコーポレイテッド | Il-2スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
JP7383605B2 (ja) * | 2017-06-25 | 2023-11-20 | システィミューン, インク. | 抗pd-l1抗体とその作製及び使用方法 |
SG11202000660QA (en) * | 2017-07-27 | 2020-02-27 | Iteos Therapeutics Sa | Anti-tigit antibodies |
WO2019030377A1 (en) * | 2017-08-11 | 2019-02-14 | Blink Biomedical Sas | CD96 BINDING AGENTS AS IMMUNOMODULATORS |
CN113004417A (zh) * | 2017-09-07 | 2021-06-22 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
EP3689909A4 (de) | 2017-09-29 | 2021-12-29 | Jiangsu Hengrui Medicine Co., Ltd. | Tigit-antikörper, antigenbindendes fragment davon und medizinische verwendung davon |
CA3077509A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
KR20200068659A (ko) | 2017-10-11 | 2020-06-15 | 오리진 디스커버리 테크놀로지스 리미티드 | 3-치환된 1,2,4-옥사다이아졸의 결정질 형태 |
JP7378394B2 (ja) | 2017-11-03 | 2023-11-13 | オーリジーン オンコロジー リミテッド | Tim-3およびpd-1経路の二重阻害剤 |
EP3706798A1 (de) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Gemeinsame therapien zur immunmodulation |
CN108254557B (zh) * | 2017-12-26 | 2019-05-31 | 首都医科大学附属北京地坛医院 | 用cd8阳性的t细胞上pd-1和tigit确定hbv相关原发性肝癌预后的系统 |
CA3082280A1 (en) | 2017-12-28 | 2019-07-04 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against tigit |
TWI816729B (zh) * | 2017-12-30 | 2023-10-01 | 英屬開曼群島商百濟神州有限公司 | 抗tigit抗體及其作為治療和診斷的用途 |
US20190269664A1 (en) | 2018-01-08 | 2019-09-05 | Chemocentryx, Inc. | Methods of treating solid tumors with ccr2 antagonists |
JP7156607B2 (ja) | 2018-02-06 | 2022-10-19 | アイ-エムエービー バイオファーマ (ハンジョウ) カンパニー リミテッド | Igおよびitimドメインを持つt細胞免疫受容体(tigit)に対する抗体およびその使用 |
AU2019218136A1 (en) | 2018-02-08 | 2020-08-13 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
CN111836831A (zh) * | 2018-02-26 | 2020-10-27 | 豪夫迈·罗氏有限公司 | 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药 |
MX2020008795A (es) | 2018-02-28 | 2020-10-08 | Yuhan Corp | Anti cuerpos anti tigit y usos de los mismos. |
US20210379024A1 (en) * | 2018-03-14 | 2021-12-09 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
CN108546298B (zh) * | 2018-03-29 | 2021-05-14 | 中国人民解放军军事科学院军事医学研究院 | 一种特异性结合pd-1的单克隆抗体 |
CN108546299B (zh) * | 2018-03-29 | 2019-09-24 | 中国人民解放军军事科学院军事医学研究院 | 解除pd-1对机体免疫抑制的靶向分子 |
SG11202011461TA (en) | 2018-06-01 | 2020-12-30 | Compugen Ltd | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
EP3813880A4 (de) | 2018-06-29 | 2022-07-13 | Gensun Biopharma Inc. | Antitumor-immunotestpunktregulator antagonisten |
SG11202100746WA (en) | 2018-07-25 | 2021-03-30 | Innovent Biologics Suzhou Co Ltd | Anti-tigit antibody and use thereof |
AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
WO2020081764A1 (en) * | 2018-10-18 | 2020-04-23 | Synerk Inc. | Compositions and methods for inhibiting tigit gene expression |
AU2019379576A1 (en) | 2018-11-13 | 2021-06-03 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
CN109448790B (zh) * | 2018-11-19 | 2021-11-09 | 上海科技大学 | 一种确定肿瘤免疫治疗标志物的存储介质、设备及装置 |
AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
EP3725370A1 (de) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modifizierte anti-pd-l1-antikörper und verfahren und verwendungen zur behandlung einer neurodegenerativen erkrankung |
TWI760751B (zh) * | 2019-05-29 | 2022-04-11 | 美商美國禮來大藥廠 | Tigit及pd-1/tigit-結合分子 |
CN110128550B (zh) * | 2019-05-30 | 2023-01-13 | 南京惟亚德生物医药有限公司 | 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用 |
US10851157B2 (en) | 2019-07-01 | 2020-12-01 | Gensun Biopharma, Inc. | Antagonists targeting the TGF-β pathway |
AU2020314129A1 (en) | 2019-07-15 | 2022-02-24 | Shanghai Junshi Biosciences Co., Ltd. | Anti-tigit antibodies and application thereof |
US20220251194A1 (en) * | 2019-07-30 | 2022-08-11 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3/tigit trispecific antibodies and anti-pd-1/lag3 bicpecific antibodies |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
US11667709B2 (en) | 2019-09-24 | 2023-06-06 | Industrial Technology Research Institute | Anti-TIGIT antibodies and methods of use |
CA3155173A1 (en) | 2019-09-27 | 2021-04-01 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
WO2021086889A1 (en) * | 2019-10-29 | 2021-05-06 | Chinook Therapeutics, Inc. | Methods and compositions for treatment of cancer and infectious diseases |
US20230057899A1 (en) | 2019-12-05 | 2023-02-23 | Compugen Ltd. | Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killing |
CA3170025A1 (en) | 2020-03-13 | 2021-09-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pvrig binding protein and its medical uses |
CN113563470B (zh) * | 2020-04-29 | 2023-02-10 | 广州昂科免疫生物技术有限公司 | 结合tigit抗原的抗体及其制备方法与应用 |
CN114507284B (zh) | 2020-05-09 | 2023-05-26 | 华博生物医药技术(上海)有限公司 | 抗tigit的抗体、其制备方法和应用 |
JP2023528036A (ja) | 2020-06-02 | 2023-07-03 | アーカス バイオサイエンシズ インコーポレイティド | Tigitに対する抗体 |
BR112022025801A2 (pt) | 2020-06-18 | 2023-10-03 | Hoffmann La Roche | Métodos para tratar um paciente e para tratar um paciente com escc avançado, kit, anticorpo, uso de um anticorpo e uso de um antagonista de ligação |
AU2021306613A1 (en) | 2020-07-07 | 2023-02-02 | BioNTech SE | Therapeutic RNA for HPV-positive cancer |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
CN115708865A (zh) * | 2020-08-25 | 2023-02-24 | 沣潮医药科技(上海)有限公司 | Tigit免疫粘附素在制备调节血管生成产品中的应用 |
WO2022044010A1 (en) | 2020-08-26 | 2022-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-t-cell immunoglobulin and itim domain (tigit) antibodies for the treatment of fungal infections |
KR102647295B1 (ko) * | 2020-09-03 | 2024-03-14 | 한국과학기술연구원 | 암 면역 치료의 효능 예측을 위한 바이오마커 및 이의 용도 |
CN114539418A (zh) | 2020-11-26 | 2022-05-27 | 上海华奥泰生物药业股份有限公司 | 双特异性抗体及其用途 |
US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
WO2022152245A1 (zh) | 2021-01-14 | 2022-07-21 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体药物组合物及其用途 |
BR112023020662A2 (pt) * | 2021-04-09 | 2024-02-06 | Seagen Inc | Métodos de tratamento de câncer com anticorpos anti-tigit |
TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗tigit抗體、抗cd96抗體及其使用方法 |
CA3218590A1 (en) | 2021-06-07 | 2022-12-15 | Providence Health & Services - Oregon | Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use |
WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
TW202320848A (zh) | 2021-07-28 | 2023-06-01 | 美商建南德克公司 | 治療癌症之方法及組成物 |
CA3231553A1 (en) | 2021-09-15 | 2023-03-23 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising anti-pvrig/tigit bispecific antibody |
TW202328195A (zh) | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合pd-1的蛋白及其醫藥用途 |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
WO2023178192A1 (en) | 2022-03-15 | 2023-09-21 | Compugen Ltd. | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
CN116444675B (zh) * | 2023-05-11 | 2023-12-22 | 亲和(武汉)生命科技有限责任公司 | 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用 |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
WO1992009300A1 (en) | 1990-11-21 | 1992-06-11 | Iterex Pharmaceuticals Ltd. Partnership | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Hiv感染治療のための異種複合抗体 |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
US5989811A (en) | 1994-09-29 | 1999-11-23 | Urocor, Inc. | Sextant core biopsy predictive mechanism for non-organ confined disease status |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP1978033A3 (de) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Aus immunisiertem Xenomid abgeleitete menschliche Antikörper |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5750345A (en) | 1995-10-31 | 1998-05-12 | Evanston Hospital Corporation | Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders |
WO1998023761A1 (en) | 1996-11-27 | 1998-06-04 | Genentech, Inc. | HUMANIZED ANTI-CD11a ANTIBODIES |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
WO1999063063A1 (en) | 1998-06-03 | 1999-12-09 | Northwestern University | Cellular proteins which mediate herpesvirus entry |
US6518033B1 (en) | 1998-08-05 | 2003-02-11 | The Research Foundation Of State University Of New York | Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment |
EP1220905A2 (de) | 1999-03-08 | 2002-07-10 | Genentech Inc. | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten |
EP1173462A1 (de) | 1999-03-26 | 2002-01-23 | Human Genome Sciences, Inc. | 50 menschlische sekretierte hormone |
US7282570B2 (en) | 1999-04-20 | 2007-10-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
CA2375458A1 (en) | 1999-07-20 | 2001-01-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20080050809A1 (en) | 1999-09-28 | 2008-02-28 | Alejandro Abuin | Novel human kinases and polynucleotides encoding the same |
WO2001029221A2 (en) | 1999-10-20 | 2001-04-26 | Zymogenetics, Inc. | Proteins and polynucleotides encoding them |
US20040219521A1 (en) | 2000-01-21 | 2004-11-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
AU2001249727A1 (en) | 2000-03-31 | 2001-10-15 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
WO2001075116A2 (en) | 2000-04-04 | 2001-10-11 | Schering Corporation | ISOLATED NUCLEIC ACIDS FROM MICROMONOSPORA ROSARIA PLASMID pMR2 AND VECTORS MADE THEREFROM |
US6965018B2 (en) | 2000-06-06 | 2005-11-15 | Bristol-Myers Squibb Company | Antibodies directed to B7-related polypeptide, BSL-2 |
US7713705B2 (en) | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
US20040101876A1 (en) | 2002-05-31 | 2004-05-27 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
EP1504099A4 (de) | 2001-12-10 | 2006-05-10 | Nuvelo Inc | Neue nukleinsäuren und polypeptide |
AU2003211112A1 (en) | 2002-02-13 | 2003-09-04 | Incyte Corporation | Secreted proteins |
CA2476518A1 (en) | 2002-02-22 | 2003-09-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
FI2206517T3 (fi) * | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita |
US20060199181A1 (en) | 2002-09-11 | 2006-09-07 | Genentch, Inc. | Compositions and methods for the treatment of immune related diseases |
ATE493433T1 (de) | 2002-09-11 | 2011-01-15 | Genentech Inc | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
EP1481993A1 (de) | 2003-05-28 | 2004-12-01 | Xerion Pharmaceuticals AG | Modulation der Funktion des Poliovirus-Rezeptors |
PE20050928A1 (es) | 2003-11-21 | 2005-11-08 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti-igfr1 |
GB2408508A (en) | 2003-11-28 | 2005-06-01 | Astrazeneca Ab | Apolipoprotein antibodies |
CN101035807A (zh) | 2004-06-09 | 2007-09-12 | 泰勒公司 | Siglec-6相关疾病的诊断和治疗 |
AR052774A1 (es) | 2004-10-08 | 2007-04-04 | Wyeth Corp | Inmunoterapia para trastornos autoinmunes |
EP3530736A3 (de) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Humane monoklonale antikörper für den programmierten tod 1 (pd-1) und verfahren zur behandlung von krebs mit pd-1-antikörpern allein oder in kombination mit anderen immunotherapeutika |
EP1891107B1 (de) | 2005-05-12 | 2011-07-06 | ZymoGenetics, Inc. | Zusammensetzungen und verfahren zur modulierung von immunreaktionen |
SI1907424T1 (sl) | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
US20100075377A1 (en) | 2006-04-13 | 2010-03-25 | West James W | Tetramerizing polypeptides and methods of use |
WO2007124283A2 (en) | 2006-04-13 | 2007-11-01 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
CA2648925A1 (en) | 2006-04-13 | 2007-10-25 | Zymogenetics, Inc. | Tetramerizing polypeptides and methods of use |
WO2007124383A2 (en) | 2006-04-19 | 2007-11-01 | Oregon Health & Science University | 1,1'-binaphthyl-based inhibitors of nad+-dependent deacetylase activity and sir2-family members |
DE102008028564A1 (de) * | 2007-07-03 | 2009-01-08 | Luk Lamellen Und Kupplungsbau Beteiligungs Kg | Hydrauliksystem zum Erzeugen eines Vorsteuerdruckes zum Ansteuern einer Getriebekomponente |
PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
EP2279412B1 (de) * | 2008-04-09 | 2017-07-26 | Genentech, Inc. | Neue zusammensetzungen und verfahren zur behandlung von immunkrankheiten |
US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
EP2504028A4 (de) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | Simultane hemmung von pd-l1/pd-l2 |
US8540689B2 (en) * | 2010-05-14 | 2013-09-24 | Medindica-Pak, Inc | NuChain NuPurposing container conditioning method and apparatus |
BR112012031329A2 (pt) | 2010-06-09 | 2016-10-11 | Zymogenetics Inc | proteínas de fusão diméricas vstm3 e composições e métodos relacionados |
TW201840336A (zh) * | 2011-08-01 | 2018-11-16 | 美商建南德克公司 | 利用pd-1軸結合拮抗劑及mek抑制劑治療癌症之方法 |
US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
RS58528B1 (sr) | 2012-12-03 | 2019-04-30 | Bristol Myers Squibb Co | Poboljšanje anti-kancerske aktivnosti imunomodulatornih fc fuzionih proteina |
BR112015013127A2 (pt) | 2012-12-04 | 2017-09-26 | Oncomed Pharm Inc | imunoterapia com agentes de ligação |
CN103073644B (zh) | 2012-12-31 | 2014-03-12 | 中国科学技术大学 | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 |
EP2948475A2 (de) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Verfahren und zusammensetzungen zur modulierung einer immunantwort |
CA2905798C (en) | 2013-03-15 | 2023-01-24 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
MY183503A (en) * | 2013-07-16 | 2021-02-23 | Genentech Inc | Method of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
EP3043819A4 (de) | 2013-09-11 | 2017-04-05 | Compugen Ltd. | Anti-vstm5-antikörper und verwendung davon in der therapie und diagnose |
HUE047699T2 (hu) | 2013-12-17 | 2020-05-28 | Hoffmann La Roche | Eljárások rákbetegségek kezelésére PD-1-tengelyhez kötõdõ antagonisták és taxánok alkalmazásával |
WO2015153514A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
CR20160500A (es) | 2014-03-31 | 2016-12-14 | Genentech Inc | Anticuerpos anti-ox40 y métodos de uso |
CN107073108A (zh) | 2014-07-16 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 使用tigit抑制剂和抗癌剂治疗癌症的方法 |
CA2963281A1 (en) | 2014-10-03 | 2016-04-07 | Novartis Ag | Combination therapies |
WO2016073282A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
JP6764474B2 (ja) | 2015-09-25 | 2020-09-30 | ジェネンテック, インコーポレイテッド | 抗tigit抗体及び使用方法 |
EP3471754A1 (de) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1-antikörper |
-
2014
- 2014-07-16 MY MYPI2016000061A patent/MY183503A/en unknown
- 2014-07-16 RU RU2019129525A patent/RU2019129525A/ru unknown
- 2014-07-16 WO PCT/US2014/046896 patent/WO2015009856A2/en active Application Filing
- 2014-07-16 JP JP2016527082A patent/JP6636920B2/ja active Active
- 2014-07-16 US US14/333,375 patent/US9873740B2/en active Active
- 2014-07-16 HU HUE14750063A patent/HUE050496T2/hu unknown
- 2014-07-16 RU RU2016104880A patent/RU2702108C2/ru active
- 2014-07-16 RS RS20201096A patent/RS60826B1/sr unknown
- 2014-07-16 EP EP20180144.6A patent/EP3789036A1/de active Pending
- 2014-07-16 PT PT147500631T patent/PT3021869T/pt unknown
- 2014-07-16 MX MX2016000510A patent/MX2016000510A/es unknown
- 2014-07-16 LT LTEP14750063.1T patent/LT3021869T/lt unknown
- 2014-07-16 DK DK14750063.1T patent/DK3021869T3/da active
- 2014-07-16 AU AU2014290069A patent/AU2014290069B2/en active Active
- 2014-07-16 SG SG11201600310QA patent/SG11201600310QA/en unknown
- 2014-07-16 CA CA2916681A patent/CA2916681A1/en active Pending
- 2014-07-16 EP EP14750063.1A patent/EP3021869B1/de active Active
- 2014-07-16 KR KR1020237025935A patent/KR20230118704A/ko not_active Application Discontinuation
- 2014-07-16 KR KR1020227009557A patent/KR20220042248A/ko not_active IP Right Cessation
- 2014-07-16 PL PL14750063T patent/PL3021869T3/pl unknown
- 2014-07-16 KR KR1020167000662A patent/KR20160030936A/ko not_active Application Discontinuation
- 2014-07-16 TW TW103124482A patent/TWI685349B/zh active
- 2014-07-16 BR BR112016000853A patent/BR112016000853A2/pt not_active Application Discontinuation
- 2014-07-16 TW TW109103414A patent/TW202100181A/zh unknown
- 2014-07-16 SI SI201431658T patent/SI3021869T1/sl unknown
- 2014-07-16 CN CN201480047388.9A patent/CN105492025A/zh active Pending
- 2014-07-16 ES ES14750063T patent/ES2819209T3/es active Active
-
2015
- 2015-12-24 IL IL243324A patent/IL243324B/en active IP Right Grant
-
2016
- 2016-01-14 MX MX2021008064A patent/MX2021008064A/es unknown
- 2016-05-03 HK HK16105008.1A patent/HK1217283A1/zh unknown
- 2016-08-17 US US15/239,569 patent/US10611836B2/en active Active
- 2016-08-17 US US15/239,524 patent/US10626174B2/en active Active
-
2018
- 2018-01-05 ZA ZA2018/00079A patent/ZA201800079B/en unknown
-
2019
- 2019-03-29 AU AU2019202195A patent/AU2019202195A1/en not_active Abandoned
- 2019-12-18 JP JP2019227933A patent/JP7016341B2/ja active Active
-
2020
- 2020-03-13 US US16/818,820 patent/US20200399366A1/en not_active Abandoned
- 2020-09-03 HR HRP20201404TT patent/HRP20201404T1/hr unknown
-
2021
- 2021-04-21 AU AU2021202413A patent/AU2021202413A1/en active Pending
- 2021-05-25 IL IL283429A patent/IL283429A/en unknown
- 2021-07-02 US US17/367,133 patent/US20210332132A1/en not_active Abandoned
- 2021-07-02 US US17/367,094 patent/US20210340253A1/en not_active Abandoned
- 2021-09-29 JP JP2021158842A patent/JP2022023077A/ja not_active Withdrawn
- 2021-12-17 ZA ZA2021/10554A patent/ZA202110554B/en unknown
-
2023
- 2023-06-14 US US18/334,531 patent/US20240166741A1/en active Pending
- 2023-10-13 JP JP2023177287A patent/JP2024016044A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283429A (en) | Methods for cancer treatment using PD-1 axis binding antagonists and TIGIT inhibitors | |
IL274059B (en) | Methods for treating cancer using axis 1-pd antagonists and mek inhibitors | |
IL272687A (en) | Cancer treatment methods using PD-L1 axis binding antagonists and VEGF antagonists | |
IL245857A0 (en) | Methods for the treatment of cancers using pd-1 spindle-binding antagonists and taxanes | |
IL270943A (en) | Biomarkers and methods for the treatment of 1-PD and PD-L1 related conditions | |
IL246183A0 (en) | Methods for cancer treatment using pd-1 spindle-binding antagonists and anti-cd20 antibody | |
HK1232119A1 (zh) | 用於治療癌症的檢查點抑制劑和治療劑的組合 | |
PL2999789T3 (pl) | Sposób selekcjonowania inhibitorów domeny pin hdis3 oraz zastosowanie inhibitorów domeny pin hdis3 do leczenia nowotworu |